MedTrace Logo

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

NCT01444456 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1262

Last updated 2017-03-20

Study results available
· View outcomes & findings →

Summary

This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric) and who are receiving darbepoetin alfa (Aranesp®) or other erythropoiesis-stimulating agent (ESA) to treat symptomatic anaemia.

Quality of Life will be assessed electronically with the aim of estimating improvement in quality of life for those patients receiving darbepoetin alfa (Aranesp®) who also have an increase in haemoglobin (Hb) of ≥1 g/dL

Conditions

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-08-31

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Poland
  • Romania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01444456 on ClinicalTrials.gov